Talquetamab Side Effect Management image

Talquetamab Side Effect Management

Sep 17, 2024
04:00PM - 05:00PM EDT
Online Event
Overview

While dealing with side effects related to your myeloma treatment can be tricky, information is power. Join us as Dr. Cesar Rodriguez discusses talquetamab side effect management. Wether it is a treatment you are currently receiving or one you may receive in the future, knowing what side effects you may experience and how to deal with them could make your treatment more comfortable.

Agenda
4:00 PM
Introductions
Cynthia Cahoon, RN

Cynthia introduces the agenda of the event and featured speaker Dr. Cesar Rodriguez

4:05 PM
Presentation
Cesar Rodriguez, MD

Dr. Rodriguez discusses talquetamab side effect management

4:35 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators
Healthtree contact Cynthia Cahoon, RN

Cynthia Cahoon, RN

Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.
Healthtree contact Cesar Rodriguez, MD

Cesar Rodriguez, MD

Dr. Cesar Rodriguez is Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, and the Center of Excellence for Multiple Myeloma, and serves as Clinical Director of Multiple Myeloma at The Mount Sinai Hospital. Dr. Rodriguez has extensive experience treating patients with plasma cell disorders. He is a member of the International Myeloma Working Group which conducts collaborative research and produces consensus guidelines for the myeloma community. Dr. Rodriguez has more than 10 years of experience in clinical research and is the principal investigator of numerous clinical trials for multiple myeloma focused on early drug development and immunotherapies that include T cell and NK cell directed therapies. He is also working on a 3D organoid model to better understand the biology of the tumor niche.